SeekingAlpha · Apr 27, 2026
Ligand Pharmaceuticals Incorporated (LGND) XOMA Royalty Corporation - M&A Call - Slideshow
2026-04-27. The following slide deck was published by Ligand Pharmaceuticals Incorporated in conjunction with this event.
OTC · LGNDZ
Ligand Pharmaceuticals, Inc.
Healthcare · Medical - Pharmaceuticals
$0.00
Down-$0.00 (-15.00%)
Updated Sep 11, 2026, 11:28 PM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 157.46K
- P/E ratio
- 99
- Dividend yield
- 0.00%
- 52-week range
- $0.00 – $0.02
- Volume
- 5K
- Avg. volume
- 56.76K
Price performance
LGNDZ price history
1M range · 0 trading sessions · Daily adjusted prices
LGNDZ does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest LGNDZ news
The latest Smart Investors Daily articles mentioning LGNDZ.
Stock researchCompany · Overview
LGNDZ research
Overview
Company profile and research snapshot.
Company profile
LIGAND PHARMS INC CVR
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- —
- Implied upside
- —
- Analysts
- 13
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | Leerink Partners | Outperform | — |
| Aug 7, 2026 | RBC Capital | Outperform | — |
| Aug 6, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 3, 2026 | Oppenheimer | Outperform | — |
| Jul 21, 2026 | Citigroup | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Apr 27, 2026
Ligand Pharmaceuticals Incorporated (LGND) M&A Call Transcript
Ligand Pharmaceuticals Incorporated (LGND) M&A Call April 27, 2026 8:00 AM EDTCompany ParticipantsMelanie HermanTodd Davis - CEO & DirectorOctavio...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
